Scienture Launches Commercial Sales of Arbli™, the First FDA-Approved Ready-to-Use Losartan Suspension
$256 million U.S. market opportunity drives expansion as company kicks off multi-channel promotional campaign Scienture Holdings (SCNX) announced the official ...










